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Abstract. Endomannosidase provides an alternate glu-
cose-trimming pathway in the Golgi apparatus. How-
ever, it is unknown if the action of endomannosidase is 
dependent on the conformation of the substrate. We have 
investigated the processing by endomannosidase of the 
α1-antitrypsin oligosaccharides and its disease-causing 
misfolded Z and Hong Kong variants. Oligosaccharides 
of wild-type and misfolded α1-antitrypsin expressed in 
castanospermine-treated hepatocytes or glucosidase II-
deficient Phar 2.7 cells were selectively processed by en-
domannosidase and subsequently converted to complex 
type oligosaccharides as indicated by Endo H resistance 
and PNGase F sensitivity. Overexpression of endoman-
nosidase in castanospermine-treated hepatocytes resulted 
in processing of all oligosaccharides of wild-type and 
variants of α1-antitrypsin. Thus, endomannosidase does 
not discriminate the folding state of the substrate and pro-
vides a back-up mechanism for completion of N-glyco-
sylation of endoplasmic reticulum-escaped glucosylated 
glycoproteins. For exported misfolded glycoproteins, this 
would provide a pathway for the formation of mature oli-
gosaccharides important for their proper trafficking and 
correct functioning.
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Introduction
Folding and glycosylation are closely related important 
processes for de novo synthesized proteins. They are as-
sisted and monitored by chaperones, the endoplasmic 
reticulum (ER) lectins calnexin and calreticulin, gluco-
sidase I and II, and UDP-glucose:glycoprotein glucosyl-
transferase, which are components of the quality control 
of protein folding [1, 2]. Immature or improperly folded 
glycoproteins will be recognized and re-glucosylated by 
glucosyltransferase, enter the calnexin/calreticulin cycle 
and exit it through glucose-trimming by glucosidase II. 
Thus, re-glucosylation and de-glucosylation are impor-
tant aspects in the quality control of glycoprotein fold-
ing [3–5]. An alternate glucosidase-independent pathway 
of glucose trimming is provided by endo-α-mannosidase 
[6–9]. Endomannosidase is not inhibited by glucosidase 
inhibitors and compensates for the glucosidase II-defi-
ciency in Phar 2.7 cells, and therefore maintains the abil-
ity to synthesize complex type oligosaccharides [10]. 
Importantly, endomannosidase has been shown to carry 
out a substantial amount of de-glucosylation in vivo [11]. 
It acts not only on mono-glucosylated but also on di- and 
tri-glucosylated oligosaccharides, even with truncated 
mannose chains, which are poor substrates for gluco-
sidase II [6, 9, 10]. The endomannosidase-generated 
Man7–4GlcNAc2-R oligosaccharide is not a substrate for 
the glucosyltransferase but for Golgi mannosidases. The 
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processing activity of these mannosidases is essential for 
the maturation to hybrid and complex oligosaccharides.
Endomannosidase is located in cis and medial Golgi cis-
ternae and to lesser amounts in pre-Golgi intermediates 
[12], which is different from the distribution of glucosi-
dase II [12, 13] and glucosyltransferase [14]. This indi-
cates that glucose trimming of N-linked oligosaccharides 
is not restricted to the ER but also occurs in the Golgi 
apparatus and pre-Golgi intermediates by endomannosi-
dase. This would ensure that glucosylated glycoproteins 
exported from the ER based on ER-assisted folding [15] 
can be de-glucosylated and processed to mature oligosac-
charides. Alternatively, endomannosidase could function 
in quality control of glycoprotein folding in compart-
ments distal to the ER, i.e. pre-Golgi intermediates or 
Golgi apparatus. However, it is not known if endoman-
nosidase discriminates misfolded from correctly folded 
glycoproteins similar to glucosyltransferase [1].
The function of endomannosidase as a processing en-
zyme was established by in vitro experiments analyzing 
the processing of the N-linked oligosaccharides of the ve-
sicular stomatitis virus G protein of virus-infected cells 
[16]. We have established an expression system using the 
well-characterized human hepatic α1-antitrypsin and its 
naturally occurring genetic variants, the Z and Hong Kong 
variants. Misfolded α1-antitrypsin variants cause α1-an-
titrypsin deficiency because, due to different degree of 
misfolding [17, 18], they are either completely retained 
and degraded or partially secreted by hepatocytes [19]. 
This in vivo situation resembles a cell culture system for 
transthyretin disease-associated variants in which global 
protein energetics were found to determine the extent of 
protein export [15]. Thus, α1-antitrypsin represents a 
convenient model glycoprotein to investigate whether the 
endomannosidase action is dependent on the conforma-
tion of the substrate. We expressed the wild-type and mu-
tant α1-antitrypsin in rat hepatocytes and in endomanno-
sidase-deficient CHO cells under glucosidase blockade 
as well as in glucosidase II-deficient Phar 2.7 cells. We 
show that endomannosidase acts on both native and mis-
folded variants of α1-antitrypsin, establishing its func-
tion as a Golgi apparatus-located back-up mechanism for 
protein N-glycosylation.
Materials and methods
Reagents and antibodies. Restriction enzymes, T4 DNA 
ligase, endoglycosidase H (Endo H), recombinant N-gly-
cosidase F (PNGase F) and protease inhibitor tablets were 
purchased from Roche Diagnostics (Rotkreuz, Switzer-
land), reverse transcription system from Promega (Wal-
lisellen, Switzerland), Taq DNA polymerase, 5′ RACE 
system, expression vectors pcDNA3.1 and pcDNA6/myc-
His, competent E. coli DH5α cells, Lipofectamine 2000, 
cell culture media and fetal bovine serum from Invitrogen 
(Basel, Switzerland), expression vector pMAMneo from 
Clontech (Basel, Switzerland), QIAquick PCR Purifica-
tion Kit and Plasmid Midi Kit from QIAGEN (Basel, 
Switzerland), and TRI reagent from Lucerna Chem (Lu-
cerne, Switzerland). Oligonucleotides were synthesized 
by Microsynth (Balgach, Switzerland). Castanosper-
mine, kifunensine and swainsonine were obtained from 
Toronto Research Chemicals (Toronto, Canada) and MG 
132 from Calbiochem (Lucerne, Switzerland). 35S-la-
beled methionine was purchased from Anawa Trading SA 
(Wangen, Switzerland), protein A magnetic beads from 
Dynal (Hamburg, Germany), N-butyl deoxynojirimycin 
and all other chemicals of analytical grade from Sigma 
(Buchs, Switzerland).
Polyclonal rabbit anti-rat endomannosidase antibody was 
kindly provided by Dr. R. G. Spiro (Boston, MA), poly-
clonal rabbit anti-human α1-antitrypsin antibody was 
from Dako (Zug, Switzerland), monoclonal mouse anti-
myc antibody from Promega, affinity-purified Fab frag-
ments of goat anti-rabbit IgG, goat anti-mouse IgG anti-
bodies and rhodamine red-X-conjugated affinity-purified 
Fab fragments of goat anti-rabbit IgG from Jackson Im-
munoResearch Laboratories (West Grove, PA), and Alexa 
488-conjugated (Fab′)2 fragments of goat anti-rabbit IgG 
from Molecular Probes (Eugene, OR).
Cloning of α1-antitrypsin and site-directed mutagen-
esis. Total RNA from human HepG2 cells was isolated 
using the TRI reagent and reverse transcribed with AMV 
reverse transcriptase using random primers. For subse-
quent PCR amplification, Taq DNA polymerase was used 
under standard conditions with the following α1-anti-
trypsin-specific oligonucleotides. Forward primer: 5′-
GAATTCGAATTCACAATGCCGTCTTCTGTCTCG, 
reverse primer: 5′-GAATTCCTCGAGTTATTTTTGGG-
TGGGATTCAC. The α1-antitrypsin Z variant was gen-
erated by a PCR-based site-directed mutagenesis strat-
egy. The following oligonucleotide containing the spe-
cific mutation was designed. For α1-antitrypsin Z variant 
(E342K): 5′-ACCATCGACAAGAAAGGGACT. The 
PCR products were subcloned into the EcoRI and XhoI 
sites of the expression vector pcDNA3.1. Competent E. 
coli DH5α cells were transformed with these constructs. 
Plasmid DNA was prepared using the QIAGEN plasmid 
DNA purification kit. The construct pcDNA3.1/α1-anti-
trypsin Hong Kong was kindly provided by Dr. R. Sifers 
(Dallas, TX).
Rat endomannosidase constructs. The 5′ end of the 
cDNA encoding rat endomannosidase was isolated with 
a 5′-rapid amplification of cDNA ends (5′ RACE) ap-
proach. For the 5′ RACE, a cDNA from rat liver RNA 
was synthesized containing a ligation anchored oligonu-
cleotide terminus. For PCR, an antisense gene-specific 
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primer binding to position 282–289 of the rat endoman-
nosidase (accession no. AF023657) in combination with 
the 5′ anchor primer was used. By a RT-PCR approach, 
full-length rat endomannosidase was amplified, the stop 
codon TAA deleted and a HindIII and a XhoI site was 
introduced at the 5′ and at the 3′ end of the cDNA, respec-
tively. Then, it was subcloned into the expression vector 
pcDNA6/myc-His.
Cell lines and transfections. The mouse lymphoma cell 
line Phar 2.7 was kindly provided by Dr. I. Trowbridge 
(San Diego, CA). HepG2, Clone 9 and BRL3A hepato-
cyted as well as CHO-K1 cells hepatocytes were obtained 
from American Type Culture Collection (Manassas, 
VA). BRL3A, HepG2 and Phar 2.7 cells were cultured 
in DMEM medium containing 10% fetal bovine serum 
(FBS) and clone 9 rat hepatocytes as well as CHO-K1 
cells in Ham’s F12 medium containing 10% FBS.
Transfections of clonal lines of BRL3A and clone 9 rat 
hepatocytes and of Phar 2.7 and CHO-K1 cells with the 
pcDNA3.1/α1-antitrypsin constructs were performed us-
ing Lipofectamine 2000 according to the manufacturer’s 
instructions. For selection, cells were grown in medium 
containing G418 (100 μg/ml) and clonal cell lines were 
established in 96-multiwell plates. Individual clones were 
tested for the expression of α1-antitrypsin by immuno-
fluorescence and by RT-PCR.
Phar 2.7 cells were also stably transfected with a vec-
tor containing an inducible promoter. For this, the cDNA 
coding for α1-antitrypsin was subcloned into the SmaI 
and XhoI site of the expression vector pMAM/neo con-
taining the inducible mouse mammary tumor virus pro-
moter. Cells were selected in medium containing G418 
(250 μg/ml).
Clone 9 rat hepatocytes, expressing wild-type or mutant 
α1-antitrypsin were co-transfected with the pcDNA6/
endomannosidase-myc constructs. Clonal cells were 
selected in medium containing blasticidin (8–10 μg/ml) 
and G418 (100 μg/ml) and individual clones were tested 
for the expression of recombinant myc-tagged endoman-
nosidase by immunofluorescence.
Metabolic labeling, inhibitor treatments, immuno-
precipitation and SDS-PAGE. Clonal lines of trans-
fected BRL3A, clone 9, CHO or Phar 2.7 cells, grown 
in flasks (25 cm2) to 70–80% confluence, were incubated 
in methionine-free DMEM containing dialyzed FBS for 
30 min at 37 °C. For experiments with inhibitors, the 
cells were pre-incubated at 37 °C for 1 h with medium 
containing one of the following inhibitors: castanosper-
mine (100 μg/ml), N-butyl deoxynojirimycin (100 μg/
ml), swainsonine (10 μg/ml), kifunensine (300 μM) and 
tunicamycin (1 μM). For pulse labeling, the cells were 
incubated in fresh medium, with or without inhibitors, 
containing 100 μCi/ml [35S]methionine for 20 min at 
37 °C. For the chase, the radioactive medium was re-
moved and the cells were cultured in medium containing 
cold methionine (1 mM), in the absence or presence of 
inhibitors. For proteasome inhibition, MG 132 (10 μM) 
was added to the medium during the chase period. Subse-
quently, cells were washed with ice-cold PBS, mechani-
cally removed, sedimented by centrifugation and resus-
pended in PBS containing protease inhibitors. Proteins 
were extracted with Triton X-100 (1%, 1 h at 4 °C) and 
cell debris removed by centrifugation. The cell extract or 
the corresponding culture medium was added to protein 
A magnetic beads conjugated with rabbit anti-human α1-
antitrypsin antibody and incubated for 2 h at 4 °C. The 
immunoprecipitates were washed with PBS containing 
0.1% Triton X-100 and with PBS. Immunoprecipitated 
proteins were released by boiling in Laemmli buffer and 
separated in 8% SDS-polyacrylamide gels. Radioactivity 
was visualized by autoradiography or using a phospho-
rimager (FUJI Film Corp., Japan). In addition, pulse-
chase experiments in clone 9 cells expressing the wild-
type and Z variant of α1-antitrypsin were performed at 
42 °C.
Isolation of Golgi membranes and Western blotting. 
Transfected or non-transfected clone 9 hepatocytes 
were homogenized in 250 mM sucrose, 10 mM Tris-
HCl (pH 7.4) containing protease inhibitors. Cell debris 
and nuclei were removed by centrifugation at 1000 g 
for 5 min at 4 °C, and the supernatant centrifuged at 
100 000 g for 45 min at 4 °C. The microsomal pellet 
was resuspended in PBS containing protease inhibitors, 
passed several times through a 27-G needle, and the su-
pernatant used for Western blot analysis. Proteins (20 μg 
protein/lane) were separated in 10% SDS-polyacryl-
amide gels, transferred onto nitrocellulose membranes 
using a semidry blotting apparatus [20] and probed for 
endomannosidase. The membranes were blocked with 
PBS containing 1% BSA and 0.05% Tween 20 for 1 h at 
ambient temperature and incubated with 1 μg/ml rabbit 
anti-rat endomannosidase antibody or with 0.4 μg/ml 
mouse monoclonal anti-myc antibody overnight at 4 °C 
followed by the incubation with the corresponding al-
kaline phosphatase-conjugated secondary antibody. The 
color reaction was performed as described previously 
[21].
Glycosidase digestions. For Endo H digestion, immu-
noprecipitates were boiled in 30 μl 50 mM Tris-HCl 
(pH 6.8) containing 0.1% SDS and 0.1% 2-mercaptoeth-
anol for 5 min. Then, 25 μl sodium acetate buffer (0.1 M, 
pH 5.6) containing protease inhibitors was added fol-
lowed by the addition of 5 mU Endo H. For PNGase F di-
gestion, immunoprecipitates were denatured as above and 
3 μl HEPES buffer (0.5 M, pH 7.4), 2 μl 10% Igepal, 2 μl 
1% AEBSF and 2 U PNGase F were added. All samples 
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were incubated at 37 °C for 12–16 h before SDS-PAGE 
analysis.
Confocal immunofluorescence microscopy. Cells grown 
as monolayer on glass cover slips were formaldehyde-
fixed and saponin-permeabilized as described [22]. For 
double immunofluorescence, cells were incubated with 
rabbit anti-rat endomannosidase (0.4 μg/ml) for 2 h at 
ambient temperature followed by rhodamine red-X-con-
jugated Fab fragments of goat anti-rabbit IgG (1000-fold 
diluted) for 1 h. After rinses, free rabbit IgG was blocked 
with unlabeled goat anti-rabbit Fab (12 μg/ml) followed 
by rabbit anti-human α1-antitrypsin antibody (2 μg/ml) 
for 1 h and Alexa 488-conjugated (Fab′)2 fragments of 
goat anti-rabbit IgG (1000-fold diluted) for 45 min. Dou-
ble immunofluorescence for endomannosidase and Golgi 
mannosidase II was performed as described [12]. In addi-
tion, the monoclonal anti-myc antibody (1.3 μg/ml) with 
the corresponding secondary antibody was used for clone 
9 hepatocytes transfected with pcDNA6-constructs. Af-
ter rinses in buffer and double-distilled water, coverslips 
were embedded in Moviol. Immunofluorescence was ob-
served with a Leica confocal laser scanning microscope 
TCS SP2 using the 100 × objective (1.4). In the double-
immunofluorescence overlays, effects of pixel shift were 
excluded. The z-axis resolution of the equipment was at 
maximum 300 nm per voxel and the x; y settings were 
between 50 and 250 nm per voxel.
Immunoelectron microscopy. Clone 9 rat hepatocytes 
were fixed in 3% paraformaldehyde in PBS for 10 min 
at 37 °C, followed by fixation for 20 min at ambient tem-
perature. Mechanically detached cells were sedimented 
by centrifugation, enclosed in agarose (2%) and infil-
trated with sucrose (2.0 M) containing 15% polyvinyl 
pyrrolidone (10 kDa) in the presence of 1% paraformal-
dehyde. Pieces were mounted on aluminum pins, frozen 
and stored in liquid nitrogen. Frozen ultrathin sections 
were prepared according to Tokuyasu [23, 24], picked 
up on formvar-coated nickel grids and stored overnight 
on 2 M sucrose containing 15% polyvinyl pyrrolidone at 
4 °C. Immunogold labeling for α1-antitrypsin was per-
formed on ultrathin frozen sections using the protein A-
gold technique [25].
Results
To study the possible function of endomannosidase in the 
quality control of protein folding or as a back-up mecha-
nism of protein N-glycosylation, we stably expressed hu-
man α1-antitrypsin and two naturally occurring genetic 
variants of α1-antitrypsin in clone 9 rat hepatocytes and 
transiently in BRL3A hepatocytes. The oligosaccharide 
processing by the alternate endomannosidase trimming 
pathway was analyzed in vivo under conditions of cas-
tanospermine-induced glucosidase I and II blockade. 
Both clone 9 and BRL3A hepatocytes possess high en-
domannosidase activity [12] as compared with other cell 
lines [16], and lack endogenous α1-antitrypsin based 
on Western blot analysis and RT-PCR (data not shown). 
Furthermore, glucosidase II-deficient Phar 2.7 cells [10, 
26, 27] and CHO cells lacking endomannosidase activity 
[28] were stably transfected.
Wild-type human α1-antitrypsin is a substrate for 
endomannosidase. Metabolic labeling of clonal lines 
of transfected clone 9 (Fig. 1a) or BRL3A hepatocytes 
(Fig. 1b) showed that the human α1-antitrypsin was syn-
thesized as a 52-kDa glycoprotein and rapidly secreted as 
a 56-kDa form (Fig. 1a, b), as in liver hepatocytes. The 
52-kDa form represents intracellular α1-antitrypsin with 
a high-mannose oligosaccharide structure due to process-
ing of the oligosaccharide precursors by glucosidases as 
previously reported for α1-antitrypsin in HepG2 cells 
[29]. The higher molecular mass of secreted α1-antitryp-
sin is due to the presence of complex-type oligosaccha-
rides (see also below). When synthesized in the presence 
of the glucosidase I and II inhibitor castanospermine, 
α1-antitrypsin had a molecular mass of 54 kDa because 
of the preserved Glc3Man9GlcNAc2 structure of its three 
oligosaccharides and after secretion a slightly higher 
molecular mass (Fig. 1a, b). In the presence of castano-
spermine, the secretion of wild-type α1-antitrypsin was 
marginally reduced (Fig. 1a, b).
To study the processing of the N-linked oligosaccharides 
of α1-antitrypsin in clone 9 and BRL3A hepatocytes, 
immunoprecipitates were subjected to Endo H digestion 
[30]. Intracellular α1-antitrypsin in clone 9 hepatocytes 
(Fig. 1c) was Endo H sensitive, as indicated by a shift 
in molecular mass from the 52-kDa polypeptide, repre-
senting the high mannose-type form, to the 48-kDa form, 
as observed for endogenous α1-antitrypsin in human 
HepG2 hepatocytes (data not shown). The α1-antitrypsin 
secreted by clone 9 hepatocytes was Endo H resistant, 
indicating that its oligosaccharides were of complex type 
due to Golgi processing (Fig. 1c). In contrast, α1-anti-
trypsin secreted from castanospermine-treated clone 9 
or BRL3A hepatocytes had three Endo H-resistant and 
one Endo H-sensitive species (Fig. 1c, d). This indicated 
that the tri-glucosylated oligosaccharides of α1-anti-
trypsin were processed by endomannosidase, which was 
followed by further glycosylation reactions in the Golgi 
apparatus as demonstrated by their PNGase sensitivity 
(Fig. 1c). The appearance of three Endo H-resistant spe-
cies reflects selective processing of the oligosaccharides 
of α1-antitrypsin by endomannosidase, i.e. one out of 
three oligosaccharides of α1-antitrypsin, two out of three 
or all oligosaccharides were of complex type due to the 
action of endomannosidase. The Endo H-pattern did not 
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result from an incomplete digestion in vitro since both 
prolonged incubation and higher Endo H concentrations 
did not change the pattern (not shown). This is also fully 
supported by endomannosidase overexpression experi-
ments (see below).
The α1-antitrypsin expressed in glucosidase II-deficient 
Phar 2.7 cells was synthesized as a glycoprotein with a 
molecular mass of about 54 kDa since it possessed oli-
gosaccharides with the Glc2Man9–8GlcNAc2 structure, 
which are a substrate for endomannosidase [6, 9, 10]. 
While immunoprecipitated intracellular α1-antitrypsin 
was fully Endo H-sensitive (data not shown), secreted α1-
antitrypsin showed three Endo H-resistant and one Endo 
H-sensitive species (Fig. 1e), similar to α1-antitrypsin 
secreted from the castanospermine-treated clone 9 and 
BRL3A hepatocytes (Fig. 1c, d). Taken together, this 
demonstrated that during chemical glucosidase blockade 
or in glucosidase II-deficient Phar 2.7 cells, oligosac-
charides of wild-type α1-antitrypsin were processed by 
endomannosidase that generated an oligosaccharide sub-
strate for further processing in the Golgi apparatus and 
resulted in the formation of Endo H-resistant, complex-
type oligosaccharides.
Misfolded mutants of α1-antitrypsin are detectable in 
endomannosidase containing organelles. Previously, 
we have shown that endomannosidase is present in cis 
and medial Golgi apparatus cisternae and in pre-Golgi in-
termediates [12]. Castanospermine treatment did not al-
ter the inherent distribution of endomannosidase, or that 
of Golgi mannosidase II, as shown in Figure 2a–c. Next, 
we studied the mutual distributions of α1-antitrypsin mu-
tants and endomannosidase in castanospermine-treated 
cells. By double confocal immunofluorescence, the Z 
variant of α1-antitrypsin (Fig. 2d–f) as well as the Hong 
Kong variant (data not shown) partially overlapped with 
staining for endomannosidase. This was confirmed by 
immunogold electron microscopy demonstrating label-
ing for the two variants of α1-antitrypsin in the ER, pre-
Golgi intermediates and the Golgi apparatus (Fig. 3a–c). 
The studied clonal cell lines expressed similar amounts 
of the α1-antitrypsin variants based on pulse-labeling 
experiments (data not shown). Together, these results 
demonstrate that mutant α1-antitrypsin is detectable in 
endomannosidase positive structures.
Z variant of α1-antitrypsin is processed by endoman-
nosidase. The Z variant expressed in clone 9 hepatocytes 
(Fig. 4a), in BRL3A hepatocytes (data not shown) and 
CHO cells (Fig. 4b) had a molecular mass of 52 kDa for 
Figure 1. Human α1-antitrypsin expressed in rat hepatocytes is 
processed by endomannosidase. Clone 9 rat hepatocytes (a) or 
BRL 3A hepatocytes (b) were pulsed for 20 min in the absence 
(–) or presence (+) of castanospermine and chased for the time 
period indicated. Cell lysates (IC) and culture medium (EC) were 
immunoprecipitated with anti-human α1-antitrypsin antibody and 
analyzed by 8% SDS-PAGE/fluorography. (c) In the absence of cas-
tanospermine, the intracellular α1-antitrypsin was sensitive to Endo 
H, whereas the secreted extracellular form was Endo H resistant. In 
the presence of castanospermine, Endo H digestion of the secreted 
α1-antitrypsin yielded three Endo H-resistant forms and one sensi-
tive form, which were PNGase F sensitive (d). Endo H treatment 
of secreted α1-antitrypsin of BRL3A hepatocytes in the presence 
of castanospermine gave the same result. (e) Endo H treatment of 
secreted human α1-antitrypsin expressed in the glucosidase II-de-
ficient Phar 2.7 cells resulted in three Endo H-resistant and one 
Endo H-sensitive species. The higher band intensities as compared 
with (c, d) reflect the differences of in vivo substrate specificity of 
endomannosidase.
Figure 2. Confocal immunofluorescence of endomannosidase and 
human α1-antitrypsin in clone 9 rat hepatocytes during glucosi-
dase blockade. (a–c) A single confocal section reveals a perinuclear 
crescent-shaped staining for endomannosidase (a) and for Golgi-
mannosidase II (b) which overlaps partially (c) in castanospermine-
treated clone 9 hepatocytes. The additional punctate endomannosi-
dase immunofluorescence is indicative of its presence in pre-Golgi 
intermediates. (d–f ) In clone 9 hepatocytes, stably expressed Z 
variant of α1-antitrypsin (d) and endomannosidase (e) exhibit par-
tial co-distribution ( f ). Bars, 10 μm.
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the intracellular form and 56 kDa for the secreted one 
(Fig. 4a, b) with the latter being Endo H resistant (data 
not shown), like wild-type α1-antitrypsin (Fig. 1a, b). 
The Z variant in clone 9 and BRL3A hepatocytes started 
to become secreted after a lag period of 1 h with no de-
tectable protein after a 30-min chase (Fig. 4a). However, 
in CHO cells only minor amounts were secreted after a 
lag period of 3 h (Fig. 4b). The small shift in molecular 
mass of the intracellular Z variant (Fig. 4a, b) was due to 
trimming by ER-mannosidase I since it could be inhibited 
by its specific inhibitor kifunensine [31] (Fig. 4c) but not 
by the Golgi mannosidase II inhibitor swainsonine [32] 
(data not shown).
In castanospermine-treated hepatocytes, the Z variant was 
synthesized as 54-kDa glycoprotein and secreted with the 
same kinetics as in untreated cells. Endo H treatment of 
the immunoprecipitated secreted Z variant, after 1 h of 
chase, gave three Endo H-resistant and one Endo H-sen-
sitive species. After 3 h of chase, oligosaccharides of the 
Z variant were essentially Endo H-resistant (Fig. 4d). A 
similar result was found in cells pretreated with the glu-
cosidase I inhibitor N-butyl deoxynojirimycin (Fig. 4d). 
It has been shown that the loop-sheet polymerization, i.e. 
misfolding, of the Z variant is accelerated at elevated tem-
peratures such as 42 °C [18]. When synthesized at 42 °C 
in castanospermine-treated clone 9 cells, the secreted Z 
variant was a substrate for endomannosidase as indicated 
by its Endo H resistance (Fig. 4e).
In additional experiments, we tested the effect of overex-
pression of endomannosidase on the oligosaccharide pro-
cessing of α1-antitrypsin. The myc-tagged rat endoman-
nosidase was at least threefold overexpressed in clone 9 
cells based on densitometric evaluation of Western blots 
(data not shown) without effecting its inherent cellular 
distribution (Fig. 5a). The secretion of the Z variant of 
α1-antitrypsin remained unchanged but all its three N-
linked oligosaccharides were processed as indicated by 
the presence of a single Endo H-resistant, PNGase F-sen-
sitive band (Fig. 5b). Similarly, the oligosaccharides of 
the wild-type α1-antitrypsin were completely processed 
(data not shown). These data clearly indicated that en-
dogenous endomannosidase activity levels resulted in a 
selective processing of the three N-linked oligosaccha-
rides of the wild-type and Z variant of α1-antitrypsin, 
Figure 3. Immunogold localization of mutant α1-antitrypsin in castanospermine-treated clone 9 hepatocytes. Immunogold labeling for the 
Z variant (a) and Hong Kong variant (b, c) of α1-antitrypsin is detectable in the rough endoplasmic reticulum (RER), pre-Golgi intermedi-
ates (pGI) and the Golgi apparatus (g). Bars, 0.1 μm (a, b), 0.27 μm (c).
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which is no longer observed when endomannosidase is 
overexpressed.
Terminally misfolded Hong Kong variant of α1-anti-
trypsin is a substrate of endomannosidase. The Hong 
Kong variant, a truncated α1-antitrypsin [33] synthesized 
in clone 9 hepatocytes, was retained intracellularly as a 
45-kDa protein (Fig. 6a) and partially subjected to pro-
teasomal degradation (Fig. 6b). Probably, autophagy is 
involved, as previously shown for the Z variant of α1-
antitrypsin [34]. On treatment with castanospermine, the 
Hong Kong variant with a molecular mass of 47 kDa was 
gradually secreted (Fig. 6a). On treatment with Endo H, 
three Endo H-resistant and a minor Endo H-sensitive spe-
cies were detectable (Fig. 6c), similar to that observed for 
the wild-type and Z variant of α1-antitrypsin. These data 
indicated that the oligosaccharides of the Hong Kong 
variant were trimmed by endomannosidase and further 
processed by Golgi enzymes.
Figure 4. Processing of the Z variant of α1-antitrypsin in clone 9 
cells. (a) After a chase period of 3 h, the Z variant of α1-antitrypsin 
was secreted in the medium as a 56-kDa protein in the absence 
of castanospermine and as a 54-kDa protein in the presence of 
castanospermine. (b) In contrast, most of the Z variant expressed 
in CHO cells was retained intracellularly. (c) ER-mannosidase 
I inhibition by kifunensine (Kif) abolishes the slight decrease in 
molecular mass of the intracellular Z variant during the chase. (d) 
Endo H digestion of secreted Z variant in castanospermine (CST) or 
N-butyl deoxynojirimycin (NB-DNJ)-treated clone 9 hepatocytes 
yielded three Endo H-resistant and one sensitive species. (e) Endo 
H treatment of secreted Z variant synthesized at 42 °C gave the 
same result as observed at 37 °C (see d).
Figure 5. Overexpression of myc-tagged rat endomannosidase in 
clone 9 hepatocytes resulted in complete processing of the oligo-
saccharides of the Z variant of α1-antitrypsin. (a) Double confocal 
immunofluorescence for endomannosidase-myc and Golgi-man-
nosidase II showed overlapping distributions. Bar, 10 μm. (b) The 
secreted Z variant of α1-antitrypsin in endomannosidase-overex-
pressing, castanospermine-treated clone 9 hepatocytes was Endo 
H-resistant and PNGase F-sensitive.
Figure 6. Castanospermine treatment resulted in secretion and pro-
cessing of the Hong Kong variant of α1-antitrypsin. (a) In the ab-
sence of castanospermine, the Hong Kong variant was synthesized 
as a 45-kDa protein and not secreted. The 43-kDa band represents 
the deglycosylated form of the Hong Kong variant of α1-antitryp-
sin. In the presence of castanospermine, a 47-kDa protein was se-
creted after a lag period. (b) Addition of the proteasome inhibitor 
MG132 interfered the degradation of the Hong Kong variant. (c) 
In the absence of castanospermine, the Hong Kong variant was not 
secreted and Endo H sensitive, whereas in castanospermine-treated 
clone 9 hepatocytes it was secreted and yielded three Endo H-resis-
tant and a minor Endo H-sensitive species.
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Discussion
We have previously established that endomannosidase, a 
glucose trimming endoglycosidase, resides in the Golgi 
apparatus and in pre-Golgi intermediates [12], leaving 
open the question of its possible function either as a sen-
sor of the folding state of glycoproteins or as a back-up 
mechanism for completion of N-glycosylation of ER-es-
caped glucosylated glycoproteins. Here, we have dem-
onstrated by a combination of biochemical and morpho-
logical approaches that Golgi localized endomannosidase 
acts on glucosylated oligosaccharides of both wild-type 
and misfolded variants of α1-antitrypsin. In cells with a 
blocked glucosidase I and II trimming pathway, the al-
ternate endomannosidase pathway produces an oligosac-
charide substrate for trimming by Golgi mannosidases 
and elongation by Golgi glycosyltransferases. Thus, the 
present studies demonstrate that glucose trimming by en-
domannosidase serves as a back-up mechanism for pro-
tein N-glycosylation in the Golgi apparatus. The action of 
endomannosidase provides a mechanism by which glu-
cosylated oligosaccharides of ER-escaped glycoproteins 
can be further processed to mature, functional ones and 
establishes the presence of a previously unknown func-
tion of the Golgi apparatus.
The present analysis of oligosaccharide processing by 
pulse-chase experiments with the use of Endo H and 
PNGase F in glucosidase I and II-inhibited rat hepato-
cyte cell lines and glucosidase II-deficient Phar 2.7 cells 
showed that wild-type α1-antitrypsin is a substrate for 
endomannosidase. Furthermore, the genetic variants of 
α1-antitrypsin studied were processed by endomannosi-
dase and overexpression of the enzyme increased the ef-
fect. Although there was a difference in the time course 
of secretion between wild-type and Z variant of α1-an-
titrypsin, both were processed by endomannosidase un-
der conditions of castanospermine blockade of trimming 
glucosidases. This difference in secretion was reported 
earlier by others [35, 36] and can be best explained by 
the intracellular retardation of the Z variant by the ER 
quality control. The Hong Kong variant was fully secre-
tion incompetent, but, as shown in the present study, was 
detectable not only in the ER but also in the pre-Golgi 
intermediates, which in contrast to the ER, containing 
endomannosidase [12]. This confirms and extends data 
demonstrating that misfolded proteins can escape the 
quality control in the ER proper and enter more distal 
parts of the secretory pathway from where they may be 
recycled, degraded or eventually secreted [37–39]. This 
relates to the existence of multiple checkpoints for qual-
ity control that extend beyond the ER [40–45]. As a case 
in point, in humans suffering from α1-antitrypsin defi-
ciency, the Z variant of α1-antitrypsin not only becomes 
partially secreted but is also active as a serine protease 
inhibitor [36, 46, 47]. Under our experimental condi-
tions, the Z variant of α1-antitrypsin was secreted after 
a lag period. On the other hand, the Hong Kong and the S 
variant of α1-antitrypsin [unpublished data] or misfolded 
T126M aquaporin2 [21] were recognized by the qual-
ity control of clone 9 hepatocytes, retained intracellu-
larly and degraded via the ubiquitin proteasome system. 
Therefore, we conclude that the components necessary 
for quality control are present in clone 9 rat hepatocytes. 
In this context, it is of interest that in HEK293 cells about 
40% of the Z variant is secreted [36], but in mouse hepa-
toma Hepa 1a cells [48] and CHO cells only about 15% 
is secreted, similar to that seen in patients suffering from 
α1-antitrypsin deficiency [49]. These findings support 
the notion that cell-specific folding and quality control 
systems exist. Furthermore, the molecular mechanism of 
recognition appears to depend on the glycoprotein and 
type of mutation. For instance, misfolded T126M aqua-
porin 2 is retained in the ER, whereas misfolded E258K is 
misrouted to endo/lysosomes via the Golgi apparatus [21, 
50]. Recently, it was reported that numerous pathological 
transthyretin variants were secreted with wild-type-like 
efficiency and only the most highly destabilized variants 
were subjected to ER-associated degradation in certain 
tissues [15]. It was concluded, that an ER-assisted fold-
ing pathway based on global energetics of the protein fold 
as well as protein chaperones, rather than a quality con-
trol based on wild-type stability, determined the extent 
of secretion. The proposed ER-assisted folding pathway 
might explain why in our experiments the Z variant was 
secreted, whereas the Hong Kong variant was subjected 
to ER-associated degradation. It would also provide an 
explanation for the differences in secretion among α1-
antitrypsin variants observed in patients.
We obtained data for the substrate specificity of endo-
mannosidase by studying the physiologically relevant 
α1-antitrypsin. The oligosaccharides on wild-type and 
variant α1-antitrypsin located at position 46, 83 and 247 
[49] were differentially processed by endomannosidase 
when present as tri- or di-glucosylated species. We ob-
served that endomannosidase processed both wild-type 
and misfolded variants of α1-antitrypsin, which indeed 
excludes a function as folding sensor. Classically, the ER 
is considered as the site of glucose trimming [51]. En-
domannosidase can exist in complexes with calreticulin 
in the Golgi apparatus and pre-Golgi intermediates [12, 
52]. Dissociation of calreticulin-glycoprotein complexes 
in this location can occur through endomannosidase [12–
14]. Functionally, de-glucosylation by endomannosidase 
as compared with glucosidase II has greatly differing con-
sequences. The resulting Man≤8 isomer A oligosaccharide 
is no longer a substrate for re-glucosylation by glucosyl-
transferase [3]. Thus, the action of endomannosidase will 
prevent entry into another calnexin/calreticulin cycle. 
This difference determines the fate of the glycoprotein 
since its oligosaccharides can now be processed to mature 
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ones by Golgi mannosidases and glycosyltransferases. As 
shown here for α1-antitrypsin, both the secreted variants 
and wild-type glycoproteins bear complex type oligosac-
charides. Misfolded variants of α1-antitrypsin, but also 
of other glycoproteins such as aquaporin 2, alpha-galac-
tosidase A or the CFTR chloride channel possess biologi-
cal activity and their function and proper trafficking may 
depend on proper glycosylation [53–56]. Thus, trimming 
by endomannosidase and the subsequent maturation of 
oligosaccharides in the Golgi apparatus will be poten-
tially important in case of partially secreted variants of 
misfolded glycoproteins or when pharmacological chap-
erones are applied to rescue ER-retained misfolded gly-
coproteins [56–59].
In summary, we obtained evidence that endomannosidase 
acts on both correctly folded and misfolded α1-antitryp-
sin, and propose that endomannosidase provides a back-
up mechanism for de-glucosylation of ER-escaped glyco-
proteins so that their oligosaccharides can be processed 
to mature ones. For misfolded glycoproteins, this would 
provide a pathway for the formation of mature oligosac-
charides probably important for their proper trafficking 
and correct functioning.
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